NCT05645003

Brief Summary

The aim of our study is to investigate the effect of high-frequency Repetitive Transcranial Magnetic Stimulation(rTMS) therapy applied to the dorsolateral PFC (DLPFC) area on neuropathic pain in patients with spinal cord injury. In this area, there are very few studies on the effectiveness of rTMS treatment added to medical treatment in neuropathic pain. In addition, the number of studies comparing the effect of rTMS therapy applied to the DLFPC area is very few.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2022

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 15, 2022

Completed
16 days until next milestone

First Submitted

Initial submission to the registry

December 1, 2022

Completed
8 days until next milestone

First Posted

Study publicly available on registry

December 9, 2022

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2026

Completed
Last Updated

March 9, 2026

Status Verified

March 1, 2026

Enrollment Period

3.4 years

First QC Date

December 1, 2022

Last Update Submit

March 6, 2026

Conditions

Keywords

Repetitive Transcranial Magnetic StimulationNeurological Rehabilitation

Outcome Measures

Primary Outcomes (1)

  • Change from baseline Visual Analog Scale (VAS) at 15 day and 6 week.

    It is evaluated between 0-10. 10 means severe pain, 0 means no pain. Night and day VAS assessment will be questioned.

    up to 6 week

Secondary Outcomes (5)

  • Change from baseline The Leeds Assessment of Neuropathic Symptoms & Signs Pain Scale(LANSS) at 15 day and 6 week.

    up to 6 week

  • Change from baseline Short form McGill Pain questionnaire(SF-MPQ) at 15 day and 6 week.

    up to 6 week

  • Change from baseline Short form 36 (SF-36) at 15 day and 6 week.

    up to 6 week

  • Change from baseline Beck Depression Scale at 15 day and 6 week.

    up to 6 week

  • Beck Anxiety Scale at 15 day and 6 week.

    up to 6 week

Study Arms (2)

High-frequency real-time rTMS protocol

EXPERIMENTAL

It was planned to apply a total of 1200 beats to the dorsolateral prefrontal cortex daily at a frequency of 10 HZ at 110% intensity of the motor threshold for 15 sessions.

Device: High-frequency real-time rTMS protocol

Sham rTMS Protocol

SHAM COMPARATOR

It was planned to apply daily sham rTMS to the dorsolateral prefrontal cortex for 15 sessions.

Device: Sham rTMS Protocol

Interventions

It was planned to apply a total of 1200 beats to the dorsolateral prefrontal cortex daily for 15 sessions. Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment (pregabalin, gabapentin, carbamazepine) at the same effective dose. No dose changes will be made during rTMS sessions.

High-frequency real-time rTMS protocol

It was planned to apply a to the dorsolateral prefrontal cortex daily for 15 sessions. Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment (pregabalin, gabapentin, carbamazepine) at the same effective dose. No dose changes will be made during rTMS sessions.

Sham rTMS Protocol

Eligibility Criteria

Age20 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Between the ages of 20-70, who applied to the AFSU Physical Medicine and Rehabilitation inpatient service with the diagnosis of spinal cord injury and
  • Having spinal cord injury with neurophatic pain at least six months ago,
  • Able to follow two-stage verbal commands,
  • Agreeing to participate in the study voluntarily and regularly,
  • Patients who are medically stable (no previous myocardial infarction, no musculoskeletal problems) will be included in our study.

You may not qualify if:

  • Having an important comorbid disease such as severe heart disease (aortic stenosis, angina, hypertrophic cardiomyopathy, arrhythmia, pacemaker) and uncontrolled hypertension,
  • Epilepsy,
  • History of antiepileptic drug use,
  • Intracranial metal object,
  • Presence of in-ear implant,
  • Cognitive dysfunction,
  • Lower extremity peripheral nerve injury,
  • With malignancy and active infection,
  • Infection on the skin in the application area,
  • Having an open wound,
  • Having inflammatory disease,
  • Orthopedic injuries that can limit maximum effort contractions,
  • Having a brain lesion or a history of drug use that will affect the seizure threshold,
  • Patients with increased intracranial pressure or uncontrolled migraine will not be included.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Afyonkarahisar

Afyonkarahisar, 0300, Turkey (Türkiye)

RECRUITING

Related Publications (3)

  • Nardone R, Holler Y, Langthaler PB, Lochner P, Golaszewski S, Schwenker K, Brigo F, Trinka E. rTMS of the prefrontal cortex has analgesic effects on neuropathic pain in subjects with spinal cord injury. Spinal Cord. 2017 Jan;55(1):20-25. doi: 10.1038/sc.2016.87. Epub 2016 May 31.

    PMID: 27241450BACKGROUND
  • Yang QH, Zhang YH, Du SH, Wang YC, Fang Y, Wang XQ. Non-invasive Brain Stimulation for Central Neuropathic Pain. Front Mol Neurosci. 2022 May 19;15:879909. doi: 10.3389/fnmol.2022.879909. eCollection 2022.

    PMID: 35663263BACKGROUND
  • Li L, Huang H, Yu Y, Jia Y, Liu Z, Shi X, Wang F, Zhang T. Non-invasive Brain Stimulation for Neuropathic Pain After Spinal Cord Injury: A Systematic Review and Network Meta-Analysis. Front Neurosci. 2022 Feb 11;15:800560. doi: 10.3389/fnins.2021.800560. eCollection 2021.

    PMID: 35221889BACKGROUND

MeSH Terms

Conditions

Spinal Cord InjuriesNeuralgia

Condition Hierarchy (Ancestors)

Spinal Cord DiseasesCentral Nervous System DiseasesNervous System DiseasesTrauma, Nervous SystemWounds and InjuriesPeripheral Nervous System DiseasesNeuromuscular DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Nuran EYVAZ, MD

    Afyonkarahisar Health Sciences University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Nuran EYVAZ, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

December 1, 2022

First Posted

December 9, 2022

Study Start

November 15, 2022

Primary Completion

March 31, 2026

Study Completion

March 31, 2026

Last Updated

March 9, 2026

Record last verified: 2026-03

Locations